Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 4,291 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gastro-Intestinal Cancer Clear all

Conditions: Colorectal Cancer; Lung Cancer
Interventions: TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill; Drug
Lead sponsor: Teclison Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: CRC (Colorectal Cancer)
Interventions: Ruxolitinib, Regorafenib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 57
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 54 more

Conditions: Colorectal Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 726 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III, Other Cancers in the Thoracic Region
Interventions: MRgART, LINAC; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer, Cervical Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer
Interventions: Questionnaire, Patient Navigator (PN); Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 40 Years and older
Enrollment: 2,472 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Carcinoma, Colon Carcinoma, Kidney Carcinoma, Lymphoma, Non-Small Cell Lung Carcinoma, Prostate Carcinoma
Interventions: Internet-Based Intervention, Survey Administration; Other
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 20
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 15 more

Conditions: Breast Neoplasm, Prostatic Neoplasm, Colorectal Neoplasms, Endometrial Neoplasms, Hodgkin Disease, Non Hodgkin Lymphoma
Interventions: AH-HA Tool in the EPIC EHR; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Fort Smith, Arkansas • Cedar Rapids, Iowa • Ballwin, Missouri + 8 more

Conditions: Colorectal Cancer
Interventions: Atezolizumab, Bevacizumab, Cobimetinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Aurora, Colorado • New York, New York • Nashville, Tennessee + 1 more

Conditions: Metastatic Colorectal Cancer
Interventions: Biweekly 5-FLUOROURACIL (5-FU), Biweekly Modified FOLFOX6, Biweekly FOLFIRI, mFOLFOXIRI; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
Interventions: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics); Industry
Eligibility: 18 Years and older
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 12 more

Conditions: Esophageal Cancer, Esophageal Carcinoma
Interventions: Exercise and Nutrition, Usual Care Group; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colorectal Cancer
Interventions: Racial group-targeted messages, Explicit Commitment; Other
Lead sponsor: Oakland University; Other
Eligibility: 45 Years to 80 Years
Enrollment: 799 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Michigan

Conditions: Metastatic Colorectal Cancer
Interventions: Regorafenib (Stivarga, BAY73-4506), Placebo, Best Supportive Care (BSC); Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 26
States / cities: Beverly Hills, California • Los Angeles, California • Mission Hills, California + 22 more

Conditions: Esophageal Cancer
Interventions: Telephone Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer
Interventions: bevacizumab, cetuximab, capecitabine, oxaliplatin; Biological · Drug
Lead sponsor: Herbert Hurwitz; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Durham, North Carolina • Winston-Salem, North Carolina

Conditions: Esophageal Cancer, Esophageal Neoplasms
Interventions: Prehabilitation Program; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 65 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adenomatous Polyps
Interventions: Curcuminoids; Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colon Cancer, Pancreatic Cancer, Cholangiocarcinoma, Metastatic Colon Carcinoma, Liver Metastasis
Interventions: MVT-5873, pancreatectomy or hepatectomy; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rectal Cancer
Interventions: Tissue specimen; Genetic
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Interventions: HBI-2438; Drug
Lead sponsor: HUYABIO International, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Encinitas, California • Glendale, California • Long Beach, California + 9 more

Conditions: Adenocarcinoma of the Rectum
Interventions: Midostaurin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: Bevacizumab, Docetaxel, Oxaliplatin; Biological · Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Columbus, Ohio

Conditions: Colorectal Cancer
Interventions: BLYG8824A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Duarte, California • Nashville, Tennessee

Search by objective public record fields.

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Study of Ruxolitinib in Colorectal Cancer Patients

Tissue and Serum Collection From Colorectal Cancer Patients

HEARTS Trial for Thoracic Cancers

Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities

Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)

Colorectal Cancer Screening Intervention Study

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Quality of Life After Esophagectomy for Cancer

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

Esophageal Cancer Multimodal Prehabilitation Study

Curcumin for the Chemoprevention of Colorectal Cancer

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Rectal Cancer Consortium

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Midostaurin (PKC412) for Locally Advanced Rectal Cancer

Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer